Table 2.
Inflammatory markers and CT measurements by phenotype of airflow obstruction
| COPD (n = 23) |
No COPD (n = 98) |
p-value | Asthmaa
(n = 33) |
No asthma (n = 88) |
p-value | |
|---|---|---|---|---|---|---|
| Sputum eosinophils >1.53 %, (n = 108)b | 3 (13.6) | 8 (9.3) | 0.55 | 5 (16.1) | 6 (7.8) | 0.20 |
| Sputum neutrophils (%), mean (SD) | 55.9 (19.6) | 50.6 (19.6) | 0.27 | 50.0 (22.4) | 52.4 (18.5) | 0.57 |
| C-reactive protein (mg/L), median (range) (n = 117) | 3.4 (0-74.2) | 1.1 (0-107.6) | 0.04 | 2.3 (0-77.6) | 1.1 (0-107.6) | 0.04 |
| IgE level (IU/mL) median (range) (n = 116) | 33.8 (2.2-1359.0) | 41.5 (0.8-2758.5) | 0.60 | 83.9 (5.1-1447.0) | 28.7 (0.8-2758.5) | 0.03 |
| Soluble CD163 (ng/mL), median (range) (n = 103) | 887.9 (381.5-1999.3) | 670.0 (180.1-2381.5) | 0.22 | 726.9 (324.1-2193.1) | 682.5 (180.1-2381.5) | 0.11 |
| IL-6 > median, n (%) (n = 98) | 11 (64.7) | 38 (46.9) | 0.18 | 19 (67.9) | 30 (42.9) | 0.03 |
| Adiponectin (ng/mL), median (range) (n = 115) | 5038 (0-14590) | 2822 (0-22611) | 0.10 | 2195 (0-12663) | 3713 (0-22611) | 0.07 |
| Wall area % (n = 117), mean (SD) | 47.6 (4.4) | 47.9 (5.7) | 0.84 | 51.0 (4.7) | 46.8 (5.3) | <0.001 |
| SubQ adipose volume (cm3), median (range)c | 22.9 (3.4-66.8) | 26.8 (2.9-85.1) | 0.30 | 33.3 (4.0-85.1) | 22.1 (2.9-77.7) | 0.004 |
| Mediastinal adipose volume (cm3), median (range)c | 3.3 (1.8-13.9) | 4.0 (1.1-13.5) | 0.40 | 3.9 (1.4-13.9) | 4.0 (1.1-11.6) | 0.33 |
| Mediastinal/SubQ, median (range) | 0.19 (0.08-0.63) | 0.17 (0.04-0.62) | 0.47 | 0.15 (0.06-0.58) | 0.13 (0.04-0.63) | 0.02 |
Abbreviations: SD Standard deviation, IQR interquartile range, IL Interleukin, IFN Interferon, SubQ Subcutaneous
aAsthma phenotype is defined by a history of doctor-diagnosed asthma or a bronchodilator response during pulmonary function testing
bSputum eosinophil count of 1.53 % defined as the upper limit of normal
cAdipose volume is standardized by dividing per 5 mm measured in the z-axis